Effector stage CC chemokine receptor-1 selective antagonism reduces multiple sclerosis-like rat disease

被引:33
作者
Eltayeb, S
Sunnemark, D
Berg, AL
Nordvall, G
Malmberg, Å
Lassmann, H
Wallström, E
Olsson, T
Ericsson-Dahlstrand, A
机构
[1] Karolinska Inst, Dept Med, Neuroimmunol Unit, SE-17176 Stockholm, Sweden
[2] RA CNS & Pain Control, AstraZeneca R&D Sodertalje, Dept Mol Sci, SE-15185 Sodertalje, Sweden
[3] AstraZeneca R&D Sodertalje, Safety Assessment, Dept Pathol, SE-15185 Sodertalje, Sweden
[4] AstraZeneca R&D Sodertalje, Dept Chem, SE-15185 Sodertalje, Sweden
[5] RA CNS & Pain Control, AstraZeneca R&D Sodertalje, Dept Lead Discovery, SE-15185 Sodertalje, Sweden
[6] Univ Vienna, Inst Brain Res, A-1090 Vienna, Austria
[7] Karolinska Inst, Dept Med, Rheumatol Unit, SE-17176 Stockholm, Sweden
关键词
multiple sclerosis; chemokines; macrophages; demyelination; inflammation; receptor;
D O I
10.1016/S0165-5728(03)00264-9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We have studied the role of the chemokine receptor CCR1 during the effector stage of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in DA rats. In situ hybridization histochemistry revealed local production of the CCR1 ligands CCL3 (MIP-1alpha) and CCL5 (RANTES), as well as large numbers of CCR1 and CCR5 expressing cells within inflammatory brain lesions. A low-molecular weight CCR1 selective antagonist potently abrogated both clinical and histopathological disease signs during a 5-day treatment period, without signs of peripheral immune compromise. Thus, we demonstrate therapeutic targeting of CCR1-dependent leukocyte recruitment to the central nervous system in a multiple sclerosis (MS)-like rat model. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:75 / 85
页数:11
相关论文
共 46 条
[1]  
AMOR S, 1994, J IMMUNOL, V153, P4349
[2]   Chemokines in the CNS: plurifunctional mediators in diverse states [J].
Asensio, VC ;
Campbell, IL .
TRENDS IN NEUROSCIENCES, 1999, 22 (11) :504-512
[3]   CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions [J].
Balashov, KE ;
Rottman, JB ;
Weiner, HL ;
Hancock, WW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (12) :6873-6878
[4]   Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression [J].
Baranzini, SE ;
Elfstrom, C ;
Chang, SY ;
Butunoi, C ;
Murray, R ;
Higuchi, R ;
Oksenberg, JR .
JOURNAL OF IMMUNOLOGY, 2000, 165 (11) :6576-6582
[5]  
Berger T, 1997, LAB INVEST, V76, P355
[6]   MONOCYTE-MACROPHAGE DIFFERENTIATION IN EARLY MULTIPLE-SCLEROSIS LESIONS [J].
BRUCK, W ;
PORADA, P ;
POSER, S ;
RIECKMANN, P ;
HANEFELD, F ;
KRETZSCHMAR, HA ;
LASSMANN, H .
ANNALS OF NEUROLOGY, 1995, 38 (05) :788-796
[7]   Multiple sclerosis [J].
Compston, A ;
Coles, A .
LANCET, 2002, 359 (9313) :1221-1231
[8]   The CC chemokine MIP-1α induces a selective monocyte infiltration following intradermal injection into nonhuman primates [J].
Didier, PJ ;
Paradis, TJ ;
Gladue, RP .
INFLAMMATION, 1999, 23 (01) :75-86
[9]   Modulation of experimental autoimmune encephalomyelitis: effect of altered peptide ligand on chemokine and chemokine receptor expression [J].
Fischer, FR ;
Santambrogio, L ;
Luo, Y ;
Berman, MA ;
Hancock, WW ;
Dorf, ME .
JOURNAL OF NEUROIMMUNOLOGY, 2000, 110 (1-2) :195-208
[10]   Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis [J].
Flügel, A ;
Berkowicz, T ;
Ritter, T ;
Labeur, M ;
Jenne, DE ;
Li, ZX ;
Ellwart, JW ;
Willem, M ;
Lassmann, H ;
Wekerle, H .
IMMUNITY, 2001, 14 (05) :547-560